Boron Neutron Capture Therapy and Photodynamic Therapy for High-Grade Meningiomas
Tóm tắt
Meningiomas are the most common type of intracranial brain tumors in adults. The majority of meningiomas are benign with a low risk of recurrence after resection. However, meningiomas defined as grades II or III, according to the 2016 World Health Organization (WHO) classification, termed high-grade meningiomas, frequently recur, even after gross total resection with or without adjuvant radiotherapy. Boron neutron capture therapy (BNCT) and photodynamic therapy (PDT) are novel treatment modalities for malignant brain tumors, represented by glioblastomas. Although BNCT is based on a nuclear reaction and PDT uses a photochemical reaction, both of these therapies result in cellular damage to only the tumor cells. The aim of this literature review is to investigate the possibility and efficacy of BNCT and PDT as novel treatment modalities for high-grade meningiomas. The present review was conducted by searching PubMed and Scopus databases. The search was conducted in December 2019. Early clinical studies of BNCT have demonstrated activity for high-grade meningiomas, and a phase II clinical trial is in progress in Japan. As for PDT, studies have investigated the effect of PDT in malignant meningioma cell lines to establish PDT as a treatment for malignant meningiomas. Further laboratory research combined with proper controlled trials investigating the effects of these therapies is warranted.
Từ khóa
Tài liệu tham khảo
Bondy, 1996, Epidemiology and etiology of intracranial meningiomas: A review, J. Neurooncol., 29, 197, 10.1007/BF00165649
Wiemels, 2010, Epidemiology and etiology of meningioma, J. Neurooncol., 99, 307, 10.1007/s11060-010-0386-3
Yang, 2008, Atypical and anaplastic meningiomas: Prognostic implications of clinicopathological features, J. Neurol. Neurosurg. Psychiatry, 79, 574, 10.1136/jnnp.2007.121582
Brastianos, 2019, Advances in multidisciplinary therapy for meningiomas, Neuro Oncol., 21, I18, 10.1093/neuonc/noy136
Farhood, 2018, Physical, dosimetric and clinical aspects and delivery systems in neutron capture therapy, Rep. Pract. Oncol. Radiother., 23, 462, 10.1016/j.rpor.2018.07.002
Miyatake, 2016, Boron neutron capture therapy for malignant brain tumors, Neurol. Med. Chir. (Tokyo), 56, 361, 10.2176/nmc.ra.2015-0297
Moss, 2014, Critical review, with an optimistic outlook, on Boron Neutron Capture Therapy (BNCT), Appl. Radiat. Isot., 88, 2, 10.1016/j.apradiso.2013.11.109
Kostron, 1990, Photodynamic treatment of malignant brain tumors, Wien. Klin. Wochenschr., 102, 531
Muller, 2006, Photodynamic therapy of brain tumors—A work in progress, Lasers Surg. Med., 38, 384, 10.1002/lsm.20338
Hoh, 2007, Chained lightning, Part I: Exploitation of energy and radiobiological principles for therapeutic purposes, Neurosurgery, 61, 14, 10.1227/01.neu.0000279720.83026.49
Coderre, 1999, The radiation biology of boron neutron capture therapy, Radiat. Res., 151, 1, 10.2307/3579742
Joensuu, 1999, Physical and biological targeting of radiotherapy, Acta Oncol. Suppl., 38, 75, 10.1080/028418699432806
Pisarev, 2007, Boron neutron capture therapy in cancer: Past, present and future, Arq. Bras. Endocrinol. Metabol., 51, 852, 10.1590/S0004-27302007000500024
Kraft, 1994, Biodistribution of Boron in Dogs with Spontaneous Intracranial Tumors Following Borocaptate Sodium Administration, Cancer Res., 54, 1259
Stragliotto, 1995, Biodistribution of boron sulfhydryl for boron neutron capture therapy in patients with intracranial tumors, Neurosurgery, 36, 285, 10.1227/00006123-199502000-00007
Nichols, 2002, Improved treatment planning for boron neutron capture therapy for glioblastoma multiforme using fluorine-18 labeled boronophenylalanine and positron emission tomography, Med. Phys., 29, 2351, 10.1118/1.1507780
Evangelista, 2013, Boron neutron capture therapy and 18F-labelled borophenylalanine positron emission tomography: A critical and clinical overview of theliterature, Appl. Radiat. Isot., 74, 91, 10.1016/j.apradiso.2013.01.001
Kiiski, 2007, Uptake of 4-borono-2-[18F]fluoro-L-phenylalanine in sporadic and neurofibromatosis 2-related schwannoma and meningioma studied with PET, Eur. J. Nucl. Med. Mol. Imaging, 34, 87, 10.1007/s00259-006-0154-y
Nariai, 2009, PET pharmacokinetic analysis to estimate boron concentration in tumor and brain as a guide to plan BNCT for malignant cerebral glioma, Appl. Radiat. Isot., 67, S348, 10.1016/j.apradiso.2009.03.061
Takeuchi, 2018, Boron Neutron Capture Therapy for High-Grade Skull-Base Meningioma, J. Neurol. Surg. Part B Skull Base, 79, S322, 10.1055/s-0038-1666837
Beshr, 2018, Preliminary feasibility study on differential diagnosis between radiation-induced cerebral necrosis and recurrent brain tumor by means of [18 F]fluoro-borono-phenylalanine PET/CT, Ann. Nucl. Med., 32, 702, 10.1007/s12149-018-1296-2
Kulvik, 2015, Biodistribution of boron after intravenous 4-dihydroxyborylphenylalanine-fructose (BPA-F) infusion in meningioma and schwannoma patients: A feasibility study for boron neutron capture therapy, Appl. Radiat. Isot., 106, 207, 10.1016/j.apradiso.2015.08.006
Kageji, 2015, Radiation-induced meningiomas after BNCT in patients with malignant glioma, Appl. Radiat. Isot., 106, 256, 10.1016/j.apradiso.2015.06.004
Kawaji, 2014, Effect of boron neutron capture therapy for recurrent anaplastic meningioma: An autopsy case report, Brain Tumor Pathol., 32, 61, 10.1007/s10014-014-0189-x
Kawabata, 2013, Boron neutron capture therapy for recurrent high-grade meningiomas, J. Neurosurg., 119, 837, 10.3171/2013.5.JNS122204
Aiyama, 2011, A clinical trial protocol for second line treatment of malignant brain tumors with BNCT at University of Tsukuba, Appl. Radiat. Isot., 69, 1819, 10.1016/j.apradiso.2011.04.031
Miyatake, 2009, Pseudoprogression in boron neutron capture therapy for malignant gliomas and meningiomas, Neuro Oncol., 11, 430, 10.1215/15228517-2008-107
Miyatake, 2007, Boron neutron capture therapy for malignant tumors related to meningiomas, Neurosurgery, 61, 82, 10.1227/01.neu.0000279727.90650.24
Stenstam, 2007, BNCT for recurrent intracranial meningeal tumours—Case reports, Acta Neurol. Scand., 115, 243, 10.1111/j.1600-0404.2006.00776.x
Tamura, 2006, Boron neutron capture therapy for recurrent malignant meningioma: Case report, J. Neurosurg., 105, 898, 10.3171/jns.2006.105.6.898
Miyatake, S., Kawabata, S., Yokoyama, K., Doi, A., Iida, K., Kuroiwa, T., Sakurai, Y., Maruhashi, A., and Ono, K. (2006). Boron neutron capture therapy for malignant meningiomas using epithermal neutron and 2 kinds of boron compounds with different accumulation mechanism. KURRI Prog. Rep., 148.
Miyatake, 2010, Modern radiotherapy for malignant brain tumors including the role of surgery in radiotherapy, Japanese J. Neurosurg., 19, 899, 10.7887/jcns.19.899
Miyashita, 2008, Evaluation of fluoride-labeled boronophenylalanine-PET imaging for the study of radiation effects in patients with glioblastomas, J. Neurooncol., 89, 239, 10.1007/s11060-008-9621-6
Kawabata, S., and Miyatake, S.-I. (2012). Boron Neutron Capture Therapy for Malignant Meningiomas, Springer-Verlag.
Hirose, 2019, Updated results of a phase II study evaluating accelerator-based boron neutron capture therapy (AB-BNCT) with borofalan(10B) (SPM-011) in recurrent squamous cell carcinoma (R-SCC-HN) and recurrent and locally advanced non-SCC (R/LA-nSCC-HN) of the head an, Ann. Oncol., 30, v460, 10.1093/annonc/mdz252.027
Dahlman, 1983, Laser Photoradiation Therapy of Cancer, Cancer Res., 43, 430
Kostron, 1988, Photodynamic therapy of malignant brain tumours: A phase III trial, Br. J. Neurosurg., 2, 241, 10.3109/02688698808992675
Plattner, M., Bernwick, W., and Kostron, H. (1991, January 5). Hematoporphyrin-Derivative Photodynamic In vitro Sensitivity testing for Braintumors. Proceedings of the International Conference on Photodynamic Therapy and Laser Medicine, Beijing, China.
Chen, Z., Wu, S., and Zhu, S. (1991, January 15). Adjuvant photodynamic therapy in surgical management of cerebral tumors. Proceedings of the SPIE, Beijing, China.
Powers, 1992, Current status of lasers in neurosurgical oncology, Semin. Surg. Oncol., 8, 226, 10.1002/ssu.2980080408
Marks, 1992, An in vitro study of the effect of photodynamic therapy on human meningiomas, Br. J. Neurosurg., 6, 327, 10.3109/02688699209023791
Kostron, H., Hochleitner, B.W., Obwegeser, A., and Seiwald, M. (1995, January 1). Clinical and experimental results of photodynamic therapy in neurosurgery. Proceedings of the 5th International Photodynamic Association Biennial Meeting, Amelia Island, FL, USA.
Origitano, 1993, Pal neoplasms: Investigations of photosensitizer uptake and distribution using indium-111 photofrin-ii single photon emission computed tomography scans in humans with intracranial neoplasms, Neurosurgery, 32, 357, 10.1227/00006123-199303000-00004
Tsai, 1999, Comparative study on the ALA photodynamic effects of human glioma and meningioma cells, Lasers Surg. Med., 24, 296, 10.1002/(SICI)1096-9101(1999)24:4<296::AID-LSM7>3.0.CO;2-F
Eljamel, M.S. (2009, January 13). Which intracranial lesions would be suitable for fluoresce guided resection? A prospective review of 110 consecutive lesions. Proceedings of the Progress in Biomedical Optics and Imaging—Proceedings of SPIE, Seattle, WA, USA.
Ishikawa, 2015, Critical Role of ABCG2 in ALA-Photodynamic Diagnosis and Therapy of Human Brain Tumor, Adv. Cancer Res., 125, 197, 10.1016/bs.acr.2014.11.008
Tepe, 2015, Aminolevulinic acid-mediated photodynamic therapy of human meningioma: An in vitro study on primary cell lines, Int. J. Mol. Sci., 16, 9936, 10.3390/ijms16059936
Hadjipanayis, 2019, Established and emerging uses of 5-ALA in the brain: An overview, J. Neurooncol., 141, 487, 10.1007/s11060-018-03087-7
Hefti, 2011, Susceptibility to 5-Aminolevulinic acid based photodynamic therapy in WHO i meningioma cells corresponds to ferrochelatase activity, Photochem. Photobiol., 87, 235, 10.1111/j.1751-1097.2010.00821.x
Hefti, 2012, Fluorescence guided resection and photodynamic therapy in meningiomas, J. Anal. Oncol., 1, 56, 10.6000/1927-7229.2012.01.01.8
Colditz, 2012, Aminolevulinic acid (ALA)-protoporphyrin IX fluorescence guided tumour resection. Part 2: Theoretical, biochemical and practical aspects, J. Clin. Neurosci., 19, 1611, 10.1016/j.jocn.2012.03.013
Sun, 2013, Gefitinib enhances the efficacy of photodynamic therapy using 5-aminolevulinic acid in malignant brain tumor cells, Photodiagnosis Photodyn. Ther., 10, 42, 10.1016/j.pdpdt.2012.06.003
Behbahaninia, 2013, Intraoperative fluorescent imaging of intracranial tumors: A review, Clin. Neurol. Neurosurg., 115, 517, 10.1016/j.clineuro.2013.02.019
Nokes, 2013, Aminolevulinic acid (ALA): Photodynamic detection and potential therapeutic applications, J. Surg. Res., 181, 262, 10.1016/j.jss.2013.02.002
Cornelius, 2014, Enhancing the effect of 5-aminolevulinic acid based photodynamic therapy in human meningioma cells, Photodiagnosis Photodyn. Ther., 11, 1, 10.1016/j.pdpdt.2014.01.001
Bechet, 2014, Photodynamic therapy of malignant brain tumours: A complementary approach to conventional therapies, Cancer Treat. Rev., 40, 229, 10.1016/j.ctrv.2012.07.004
Ichikawa, 2019, Photodynamic therapy with talaporfin sodium induces dose- and time-dependent apoptotic cell death in malignant meningioma HKBMM cells, Photodiagnosis Photodyn. Ther., 25, 29, 10.1016/j.pdpdt.2018.10.022
Takahashi, 2018, Photodynamic therapy using talaporfin sodium induces heme oxygenase-1 expression in rat malignant meningioma KMY-J cells, J. Toxicol. Sci., 43, 353, 10.2131/jts.43.353
Woehlck, 2003, Safe use of pulse oximetry during verteporphin therapy, Anesth. Analg., 96, 177, 10.1213/00000539-200301000-00037
Devaux, 1996, Experimental and clinical standards, and evolution of lasers in neurosurgery, Acta Neurochir. (Wien.), 138, 1135, 10.1007/BF01809742
Malham, 1996, Subcellular distribution and photocytotoxicity of aluminium phthalocyanines and haematoporphyrin derivative in cultured human meningioma cells, Br. J. Neurosurg., 10, 51, 10.1080/02688699650040520
Wilson, 1996, Determination of the activation spectrum of aluminium phthalocyanine chloride against cultured meningioma cells using a tunable laser, J. Clin. Neurosci., 3, 252, 10.1016/S0967-5868(96)90060-0
Steichen, 1991, Enhanced in vitro uptake and retention of 3H-tetraphenylphosphonium by nervous system tumor cells, J. Neurosurg., 74, 116, 10.3171/jns.1991.74.1.0116
Stummer, 1998, Technical principles for protoporphyrin-IX-fluorescence guided microsurgical resection of malignant glioma tissue, Acta Neurochir. (Wien.), 140, 995, 10.1007/s007010050206
Stummer, 2006, Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: A randomised controlled multicentre phase III trial, Lancet Oncol., 7, 392, 10.1016/S1470-2045(06)70665-9
Rebeiz, 1992, Photodestruction of tumor cells by induction of endogenouw accumulation of protoporphyrin IX: Enhancement by 1,10-phenanthroline, Photochem. Photobiol., 55, 431, 10.1111/j.1751-1097.1992.tb04258.x
Nelson, 1987, In Vivo Studies on the Utilization of Mono-L-aspartyl Chlorin (NPe6) for Photodynamic Therapy, Cancer Res., 47, 4681
Akimoto, 2012, Preliminary clinical report on safety and efficacy of photodynamic therapy using talaporfin sodium for malignant gliomas, Photodiagnosis Photodyn. Ther., 9, 91, 10.1016/j.pdpdt.2012.01.001
Muragaki, 2013, Phase II clinical study on intraoperative photodynamic therapy with talaporfin sodium and semiconductor laser in patients with malignant brain tumors, J. Neurosurg., 119, 845, 10.3171/2013.7.JNS13415